Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Wednesday, November 19, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced that it will present clinical data from the ELIMINATE-B trial at the HEP-DART 2025 conference. This presentation underscores the company's commitment to developing in vivo gene editing therapies for diseases with high unmet needs. The use of their proprietary ARCUS platform is a key aspect of their research efforts.
Price reaction · baseline $5.22 (2025-11-18 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-7.7%
day 1
-4.6%
day 3
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of clinical data indicates progress in research.
  • Focus on high unmet need diseases highlights company mission.
  • Use of proprietary ARCUS platform showcases innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Nov. 19, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will deliver an oral

Frequently Asked Questions

What is the ELIMINATE-B trial?

The ELIMINATE-B trial is a clinical study conducted by Precision BioSciences.

Where will the trial data be presented?

The trial data will be presented at the HEP-DART 2025 conference.

What platform does Precision BioSciences use?

Precision BioSciences utilizes the proprietary ARCUS platform for gene editing.

What is the focus of Precision BioSciences?

The company focuses on developing therapies for high unmet need diseases.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform clinical trial
Last updated: Nov 19, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →